Literature DB >> 29030107

Ammodytin L is the main cardiotoxic component of the Vipera ammodytes ammodytes venom.

Svjetlana Karabuva1, Boris Lukšić2, Ivica Brizić3, Zorica Latinović4, Adrijana Leonardi5, Igor Križaj6.   

Abstract

Venom of the nose-horned viper (V. a. ammodytes) as also venoms of some related European viperids can induce also cardiotoxic effects in mammals. In this work we demonstrated that the protein in the V. a. ammodytes venom acting on heart is a myotoxic secreted phospholipase A2 analogue ammodytin L (AtnL). In the isolated perfused rat heart AtnL induced significant and irreversible cardiotoxicity characterized by atrioventricular (AV) blockade. This venom protein induced appearance of high levels of creatine kinase, lactate dehydrogenase, aspartate aminotransferase and troponin I in the sinus effluent of the isolated heart, indicative for myocardial damage, which is obviously the primary cause of its cardiotoxic action. Gel filtration chromatography subfractions C1 and C2 of the V. a. ammodytes venom harboured most of the venom cardiotoxicity. As we showed, just these two subfractions contained also AtnL. Subfraction C1 in the final CF concentration 11.3 μg/mL (containing 3.1 μg/mL AtnL) induced a complete cardiac arrest while subfraction C2 in the final CF concentration 6.0 μg/mL (containing 0.8 μg/mL AtnL) and the pure AtnL (1.0 μg/mL) did not. Contrary to AtnL, subfraction C1 at 11.3 μg/mL was not able to induce the AV blockade. This exposed the only other cardiotoxic subfractions-specific venom protein, a cysteine-rich secretory protein (CRISP), as an additional venom component potentially involved in modulation of the heart activity. Cardiotoxicity reported in some cases of the adder (V. berus) venom and the asp viper (V. aspis) venom poisonings may be assigned to AtnL in these venoms.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Ammodytin L; Cardiotoxicity; Isolated rat heart; Vipera ammodytes ammodytes

Mesh:

Substances:

Year:  2017        PMID: 29030107     DOI: 10.1016/j.toxicon.2017.10.003

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  5 in total

1.  Genomic Confirmation of the P-IIIe Subclass of Snake Venom Metalloproteinases and Characterisation of Its First Member, a Disintegrin-Like/Cysteine-Rich Protein.

Authors:  Kity Požek; Adrijana Leonardi; Jože Pungerčar; Weiqiao Rao; Zijian Gao; Siqi Liu; Andreas Hougaard Laustsen; Alenka Trampuš Bakija; Katarina Reberšek; Helena Podgornik; Igor Križaj
Journal:  Toxins (Basel)       Date:  2022-03-23       Impact factor: 5.075

2.  Ambulatory electrocardiography and serum cardiac troponin I measurement in 21 dogs envenomated by the European adder (Vipera berus).

Authors:  Hannah J Harjen; Annelin A Bjelland; Joanne Harris; Tone K Grøn; Kristin P Anfinsen; Elena R Moldal; Runa Rørtveit
Journal:  J Vet Intern Med       Date:  2020-06-18       Impact factor: 3.333

3.  Cytotoxicity of snake venom Lys49 PLA2-like myotoxin on rat cardiomyocytes ex vivo does not involve a direct action on the contractile apparatus.

Authors:  Alfredo Jesús López-Dávila; Natalie Weber; Theresia Kraft; Faramarz Matinmehr; Mariela Arias-Hidalgo; Julián Fernández; Bruno Lomonte; José María Gutiérrez
Journal:  Sci Rep       Date:  2021-09-30       Impact factor: 4.379

4.  Venom-Induced Blood Disturbances by Palearctic Viperid Snakes, and Their Relative Neutralization by Antivenoms and Enzyme-Inhibitors.

Authors:  Abhinandan Chowdhury; Christina N Zdenek; Matthew R Lewin; Rebecca Carter; Tomaž Jagar; Erika Ostanek; Hannah Harjen; Matt Aldridge; Raul Soria; Grace Haw; Bryan G Fry
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

5.  Thrombocytopenic purpura following envenomation by the nose-horned viper (Vipera ammodytes ammodytes): Two case reports.

Authors:  Boris Lukšić; Svjetlana Karabuva; Joško Markić; Branka Polić; Tanja Kovačević; Julije Meštrović; Igor Križaj
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.